Doctors Warn MASLD Can Trigger Liver Cancer Before Cirrhosis as Liver Fat Tops 5%
Updated
Updated · The Times of India · May 24
Doctors Warn MASLD Can Trigger Liver Cancer Before Cirrhosis as Liver Fat Tops 5%
3 articles · Updated · The Times of India · May 24
Liver cancer can emerge in some MASLD patients before cirrhosis develops, doctors said, challenging the common assumption that cancer appears only after advanced liver scarring.
More than 5%-10% fat in the liver marks fatty liver disease, and that excess fat can drive chronic inflammation, oxidative stress and cell mutations; the injured stage is known as MASH.
Type 2 diabetes is linked to a 40%-80% chance of fatty liver disease, obesity to roughly 30%-90% of cases, and hypertension can accelerate fibrosis in about 40%-57% of affected patients.
The condition, formerly called NAFLD, is increasingly tied to obesity, poor diet, inactivity and other metabolic disorders, making MASLD a growing modern liver-health threat.
Why can 'lean' people get severe liver disease, and what genetic factors might be putting you at risk?
Fatty liver is now linked to other cancers. Are millions facing a hidden cancer risk beyond just their liver?
Is your liver's 'metabolic type' the hidden key to reversing fatty liver disease when standard diets fail?
MASLD and Liver Cancer: The Rapidly Growing Global Health Crisis Affecting 1 in 4 Adults
Overview
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a rapidly growing global health crisis, now affecting about one-fourth of adults worldwide. MASLD is not only common but is also the fastest rising cause of hepatocellular carcinoma (HCC), a severe form of liver cancer. Despite its high prevalence, MASLD often goes underdiagnosed and undertreated, mainly due to limited diagnostic methods and a lack of symptoms. This silent progression means many people are unaware they have MASLD until it leads to serious complications like liver cancer, highlighting the urgent need for better detection and management strategies.